MDMA
Psychedelic Sector News – Weekly Extractions: September 23, 2022
In this edition of Weekly Extractions, host Adam Tubero provides an update on a story we’ve been following closely over the past several weeks. For starters,…
In this edition of Weekly Extractions, host Adam Tubero provides an update on a story we’ve been following closely over the past several weeks.
For starters, MindMed’s stock has been quite volatile of late.
It all started last week with the Weekly Extractions edition from August 13th where Adam calls out a letter written to the MindMed team from Scott Freeman.
Next, Adam interviewed Scott Freeman. The video interview spanned two parts. Check out part 1 and part 2.
MindMed popped up once again on August 24th in a unique story that tied their stock to Bed Bath and Beyond.
MindMed was once again highlighted on August 27th and again in a dedicated Weekly Extractions on September 6th.
As if that wasn’t enough, the September 12th episode dove into MindMed once more.
On top of all of that, they’ve been in the press quite a bit across our website along the way:
- August 25th: MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
- September 8th: MindMed Announces Positive Results from Collaborators’ Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
- September 14th: MindMed Announces Compliance with Nasdaq Listing Requirements
- September 20th: MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
We hope you enjoy today’s Weekly Extractions – once again, dedicated to more news surrounding MindMed.
For more information on MindMed ($MNMD), check out their company profile on Psychedelic Invest.
Please like, share, comment, and subscribe on YouTube. There will be plenty more Weekly Extractions in the weeks to come.
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics1 week agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin7 days agoAre Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Law & Regulation1 week agoNuminus reports declining revenue as the company restructures
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Psychedelics7 days agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation6 days agoClearmind signs agreement with Hebrew University for psychedelic compound rights